Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

  • Authors:
    • Shoufeng Wang
    • Hong Pan
    • Desen Liu
    • Naiquan Mao
    • Chuantian Zuo
    • Li Li
    • Tong Xie
    • Dingming Huang
    • Yaoyuan Huang
    • Qi Pan
    • Li Yang
    • Junwei Wu
  • View Affiliations

  • Published online on: November 28, 2014     https://doi.org/10.3892/ijo.2014.2784
  • Pages: 809-817
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study aimed to evaluate the biological functions of excision repair cross complementation goup 1 (ERCC1) in cell proliferation, cell cycle, invasion and cisplatin response of non-small cell lung cancer (NSCLC) cells. Firstly, ERCC1 gene was successfully transfected into H1299 cells by gene cloning and transfection techniques. Then, cell proliferation was determined with the cell growth curve and colony-forming assays. Flow cytometry (FCM) was employed to investigate the cell cycle distribution. The ability of cell invasion was estimated by means of Matrigel invasion assays. Response of NSCLC cells to cisplatin was detected utilizing MTT assays, and the intracellular drug concentrations were determined by the high performance liquid chromatography (HPLC) analysis. Expression of the two cell membrane proteins, P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP), was also evaluated utilizing FCM technique. By contrast, ERCC1 expression in the NSCLC A549 cells was silenced by small interfering RNA (siRNA) through RNAi technique. In addition, the cytotoxic effect of cisplatin on A549 cells was detected by MTT assays. In the present study, the results demonstrated that ERCC1 had no effect on cell proliferation, cell cycle and the ability of invasion, but showed significant impact on cisplatin response of the NSCLC H1299 cells. Furthermore, siRNA-induced suppression of ERCC1 evidently enhanced sensitivity to cisplatin of NSCLC A549 cells. Therefore, it is confirmed that ERCC1 is a chemotherapy-tolerating gene and a promising predictor in tailoring chemotherapy of NSCLC.
View Figures
View References

Related Articles

Journal Cover

February-2015
Volume 46 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang S, Pan H, Liu D, Mao N, Zuo C, Li L, Xie T, Huang D, Huang Y, Pan Q, Pan Q, et al: Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer. Int J Oncol 46: 809-817, 2015
APA
Wang, S., Pan, H., Liu, D., Mao, N., Zuo, C., Li, L. ... Wu, J. (2015). Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer. International Journal of Oncology, 46, 809-817. https://doi.org/10.3892/ijo.2014.2784
MLA
Wang, S., Pan, H., Liu, D., Mao, N., Zuo, C., Li, L., Xie, T., Huang, D., Huang, Y., Pan, Q., Yang, L., Wu, J."Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer". International Journal of Oncology 46.2 (2015): 809-817.
Chicago
Wang, S., Pan, H., Liu, D., Mao, N., Zuo, C., Li, L., Xie, T., Huang, D., Huang, Y., Pan, Q., Yang, L., Wu, J."Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer". International Journal of Oncology 46, no. 2 (2015): 809-817. https://doi.org/10.3892/ijo.2014.2784